Category - Developments

Developments

Mereo BioPharma reports additional positive Phase 2b setrusumab data

Mereo BioPharma (NASDAQ:MREO) reported additional data from its Phase 2b ASTEROID clinical study of setrusumab in adults with Type 1, 3, and 4 osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is...

January 14, 2020

Developments

BioLineRx gets EMA orphan drug designation for pancreatic cancer drug

BioLineRx (NASDAQ:BLRX) received European Medicines Agency orphan drug designation (ODD) for motixafortide for the treatment of pancreatic cancer. Motixafortide is a short synthetic peptide designed to target CXCR4, a...

January 14, 2020

Developments

FDA clears Biocardia Morph DNA deflectable guide catheter

The FDA has granted 510(k) clearance for Biocardia’s (OTCQB:BCDA) Morph DNA deflectable guide catheter. The catheter is designed to enhance procedural control of therapeutic catheters, particularly Biocardia’s Helix...

January 14, 2020

Developments

Interface Biologics spins-out Ripple Therapeutics to focus on Epidel drug delivery technology

Closely-held Interface Biologics launched Ripple Therapeutics, a privately held, clinical stage developer of novel drugs. The launch comes four months after Interface sold its Endexo surface modification business to...

January 14, 2020

Developments

IntelGenx updates on cannabis-infused VersaFilm and RIZAPORT programs

IntelGenx (TSXV:IGX; OTCQX:IGXT) has finalized its cannabis-infused VersaFilm product with co-development partner, Tilray (NASDAQ:TLRY), and has completed manufacturing scale-up work. “Because we believe this is an...

January 13, 2020

Developments

Titan Pharma’s Probuphine added to Federal Supply Schedule

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, a novel six-month maintenance treatment for opioid use disorder (OUD), will be included on the Federal Supply Schedule (FSS) beginning on January 15, 2020. The...

January 13, 2020

Developments

Profound Medical inks its first U.S. multicenter agreement for TULSA-PRO; provides commercialization update

Profound Medical (NASDAQ:PROF; TSX:PRN) signed its first U.S. multi-site imaging center agreement for TULSA-PRO with RadNet (NASDAQ:RDNT), a leading provider of fixed-site outpatient diagnostic imaging services with a...

January 10, 2020

Developments

Law firms Troutman Sanders and Pepper Hamilton to merge

Troutman Sanders and Pepper Hamilton agreed to merge, effective on April 1, creating a new 1,100-lawyer giant with offices in 23 locations, including eight of the 10 top U.S. markets. The new firm will be known as...

January 10, 2020

Developments

BriaCell identifies new breast cancer responders based on cancer grade

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXD) identified a new group of patients with high levels of clinical benefit in response to its immunotherapy, and in combination with checkpoint inhibitors. After a reanalysis...

January 9, 2020

Developments

IntelGenx enters animal health market with VetaFilm feasibility agreement

IntelGenx (TSXV:IGX; OTCQX:IGXT) entered into a feasibility study agreement with an undisclosed partner focused on bringing innovative animal health products to the market. IntelGenx will conduct a feasibility study on...

January 9, 2020

Category - Developments

Subscribe